Gide has advised ODDO BHF SCA, as sole global coordinator and bookrunner, in connection with Carmat’s capital increase reserved for U.S. and European specialized and strategic investors for a total gross amount of approximately €60.0 million, through the issuance of 3,157,895 new shares at €19.0 per share.
Carmat, a French company listed on the Euronext growth market operated by Euronext Paris, is the designer and developer of the world’s most advanced total artificial heart project, aiming to provide a therapeutic alternative for people suffering from end-stage biventricular heart failure.
The Gide team was led by Arnaud Duhamel, partner, on French law aspects, assisted by Guilhem Richard, counsel, Mariléna Gryparis and Lou Recht, associates, and by Melinda Arsouze, partner, on U.S. law aspects, assisted by Scott Logan, senior associate. Tax aspects of the transaction were handled by Alexandre Bochu, counsel.
Jones Day advised Carmat. The Jones Day team was led by Charles Gavoty, partner, on French law aspects, assisted by Alexandre Wibaux and Patricia Jimeno, and by Linda Hesse, partner, on U.S. law aspects, assisted by Seth Engel. Tax aspects of the transaction were handled by Emmanuel de la Rochethulon, partner
Gide and Jones Day also advised respectively ODDO BHF SCA and Carmat on a previous capital increase of the company at the end of 2017.